NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc. (NGM) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ngm · pe ratio · data through Dec 31, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for NGM Biopharmaceuticals, Inc. (NGM) measures how much investors pay for each dollar of the company's trailing earnings. NGM's current PE ratio of N/A is calculated by dividing its stock price of $1.54 by its TTM earnings per share of -$1.73.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-12-31
PE Ratio History
2016 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
NGM Biopharmaceuticals, Inc.You NGM | $129M | N/A | — | -$1.73 |
 aTyr Pharma, Inc. ATYR | $43M | N/A | — | -$0.80 |
 Decibel Therapeutics, Inc. DBTX | $123M | N/A | — | -$2.52 |
 Graybug Vision, Inc. GRAY | $121M | N/A | — | -$0.00 |
 Kinnate Biopharma Inc. KNTE | $125M | N/A | — | -$2.42 |
 Pardes Biosciences, Inc. PRDS | $135M | N/A | — | -$1.61 |
 Paratek Pharmaceuticals, Inc. PRTK | $128M | N/A | — | -$1.17 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-12-31Latest FY2023 | — | $-1.73 | — | |
2022-12-31 FY2022 | — | $-1.99 | — | |
2021-12-31 FY2021 | — | $-1.48 | — | |
2020-12-31 FY2020 | — | $-1.37 | — | |
2019-12-31 FY2019 | — | $-0.57 | — | |
2018-12-31 FY2018 | — | $-0.01 | — | |
2017-12-31 FY2017 | — | $-0.26 | — | |
2016-12-31 FY2016 | — | $-0.13 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for NGM Biopharmaceuticals, Inc. (NGM) measures how much investors pay for each dollar of the company's trailing earnings. NGM's current PE ratio of N/A is calculated by dividing its stock price of $1.54 by its TTM earnings per share of -$1.73.
Frequently asked questions
NGM pe ratio · 6 questionsNGM's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.54 and TTM EPS of -$1.73. Data sourced from Financial Modeling Prep via NGM's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · NGM Biopharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09